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Objectives. We tested the hypothesis that dismutation of super- 
oxide anion increases endogenous levels of nitric oxide, resulting 
in inhibition of cyclic variations in blood flow in arteries that are 
injured and stenotic. 
Background. Platelet adhesion and aggregation leading to 
cyclic flow variations might result, in part, from generation of 
superoxide anion that can deplete ndogenously produced nitric 
oxide. 
Methods. Spontaneous cyclic flow variations, monitored with a 
proximal Doppler probe, were induced in the carotid artery of 
anesthetized rabbits by clamping the vessel with forceps and 
placing a high grade stenosis at the site of injury. Bovine 
copper/zinc superoxide dismntase (12 mg/kg body weight, n = 5), 
a synthetic low molecular weight mimetic (12 mg/kg, n = 8) or 
buffer vehicle (n = 8) was administered intravenously as divided 
boluses over 45 min, and the frequency of cyclic flow variations 
was monitored for 4 h. 
Results. Cyclic flow variations remained stable for 4 h in vehicle- 
treated animals (15 -+ 1 [mean -+ SEMI/30 rain at baseline and 16 _+ 
1/30 min after 4 h, n = 8) but exhibited a marked and persistent 
reduction i  animals given copper/zinc superoxide ismutase (from 
14 -+ 1/30 min at baseline to 4 -+ 1/30 min after 4 h) or the mimetic 
(from 15 "4- 1/30 rain at baseline to 3 - 1/30 rain after 4 h, p < 0.005). 
They were restored in three of four mimetic-treated animals during 
infusion of NG-monomethyl. L-arginine (100 mg/kg), an inhibitor of 
nitric oxide production. In addition, levels of cyclic guanosine 5'- 
monophosphate in platelets were levated after administration f the 
mimetic (from 2A "4" 0.5 fmol/106 platelets at baseline to 4.9 -+ 0.6 
linol/106 platelets 45 rain after the mimetic, p < 0.03, n = 6), whereas 
mean arterial blood pressure was decreased and flow velocity in the 
carotid artery was increased consistent with mediation of the effect 
on cyclic flow variations by increased endogenous nitric oxide. 
Conclusions. Dismutation of superoxide anion appears to at- 
tenuate platelet hrombus formation at a site of vessel injury by 
potentiation of endogenously produced nitric oxide. This ap- 
proach may have utility to inhibit platelet-rich thrombosis in 
injured and stenotic arteries where production of superoxide 
anion is increased. 
(J Am CoU Cardiol 1995;25:269-75) 
Activation of platelets has been shown to play a major role in 
the pathogenesis of unstable angina (1-3). In experimental 
animals, transient accumulation a d dislogment of platelets in 
injured and stenotic oronary arteries result in cyclic variations 
in blood flow (4,5). Analogous cyclic flow variations have been 
observed in the peripheral arteries of patients with vascular 
disease and intermittent claudication (6) and in the coronary 
arteries of patients with unstable angina undergoing angio- 
plasty (7,8). However, administration of aspirin in these pa- 
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tients frequently fails to abolish cyclic flow variations, possibly 
because it does not prevent intense and sustained activation of 
platelets in the injured vessel. 
Oxygen-derived radicals have been implicated in the gen- 
eration of cyclic flow variations after vessel injury in experi- 
mental animals (9). Superoxide anion elaborated by damaged 
endothelial cells (10), activated leucocytes (11), and smooth 
muscle cells rapidly inactivate ndothelium-derived r laxing 
factor, also identified as nitric oxide (12-15), which inhibits 
platelet adhesion and aggregation under physiologic condi- 
tions (16-19). Previous tudies (20) have shown that inhibition 
of nitric oxide production with N~-monomethyl-L-arginine 
induces cyclic flow variations in injured and stenotic oronary 
arteries in dogs. In the same study, administration of 
L-arginine, a precursor for nitric oxide synthesis, abolished 
cyclic flow variations. 
Superoxide dismutase may protect endogenous nitric oxide 
from inactivation by scavenging superoxide anion. In vitro, the 
inhibitory action of nitric oxide on aggregation of platelets as 
well as their adhesion to endothelium induced by thrombin is 
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potentiated by superoxide dismutase consistent with its pre- 
venting inactivation of endothelium-derived nitric oxide 
(12,17,21). This study was designed to test in vivo the hypoth- 
esis that superoxide dismutase, or a low molecular weight 
macrocyclic mimetic of superoxide dismutase, prevents inactiva- 
tion of endogenously produced nitric oxide, thereby attenuating 
cyclic flow variations induced by vessel injury and stenosis. 
Methods 
Animal preparations. Experiments involving animals were 
performed according to the "Position of the American Heart 
Association on Research Animal Use" adopted by the Asso- 
ciation in November 1984 and were approved by the Animal 
Studies Committee at Washington University. Forty-two New 
Zealand white rabbits weighing 2.3 to 2.5 kg were premedi- 
cated with intravenous ketamine (20 to 30 mg/kg body weight) 
and ventilated with oxygen-enriched room air containing 2% 
isoflurane. A femoral artery was cannulated for measurement 
of mean arterial blood pressure and withdrawal of blood 
samples. An ear vein was eannulated for drug administration. 
Mean arterial blood pressure and the electrocardiogram were 
monitored continuously with a four-channel recorder (model 
2000, Gould Inc.). 
A segment of the right common carotid artery was exposed 
and instrumented with a proximal Doppler probe for measur- 
ing flow velocity and frequency of cyclic flow variations. In 39 
animals, the carotid artery was gently clamped six to eight 
times with cushioned forceps at a site 1 cm distal to the 
Doppler probe. A 2.5-ram long band of polypropylene tubing 
was placed around the injured segment and constricted until 
the mean flow velocity just began to decline. This degree of 
constriction has been shown to reduce the diameter of the 
carotid artery by -75% (5). Immediately after placing the 
stenosis around the vessel, a pattern of cyclic variations in 
blood flow velocity was induced, characterized by intermittent, 
spontaneous decreases followed by abrupt increases of flow 
velocity. By carefully controlling the amount of intimal damage 
induced initially, cyclic flow variations occurred spontaneously 
and persistently for at least 4 h without additional manipula- 
tion of the stenosis. The remaining three rabbits were not 
subjected to vessel injury as a control. 
Experimental protocol. Thirty minutes after the frequency 
of cyclic flow variations had stabilized, rabbits with vessel injury 
were randomly assigned to receive either 8 mg/kg (n = 5) or 
12 mg/kg (n = 8) of a novel, synthetic manganese complex of 
a 15-membered macrocylic ligand that mimics superoxide 
dismutase (SC 52608, molecular weight 341.2, catalytic rate 
constant [kcat] = 4.13 X 107 m/s at pH 7.4 [22]) (Monsanto 
Company); 12 mg/kg (n = 5) of bovine copper/zinc superoxide 
dismutase (molecular weight 32,500, kca  t = 2.3 × 109 m/s [23] 
(Sigma Corp.); 5 mg/kg (n = 5) of a water-soluble form of 
aspirin (Asp6gic, Laboratoires Synthelabo, Paris, France) or 
10 p~g/kg per min (n = 4) of nitroglycerin over 4 h as positive 
controls; or buffer (n = 8) as a negative control. Superoxide 
dismutase and the mimetic were dissolved in 1 mmol/liter of 
N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) buffer 
(Sigma Corp.) at pH 7.4 and administered intravenously over 
1 min in divided bolus doses of 4 mg/kg at intervals of 15 rain. 
In four additional animals given 12 mg/kg of the mimetic, 
N~-monomethyl-I, arginine (100 mg/kg) (Sigma Corp.) was 
infused over 45 rain beginning 1 b after the end of the 
administration of mimetic. The remaining three animals in 
whom vessel injury was not induced received 12 mg/kg of the 
mimetic as a control. 
The frequency of cyclic flow variations and the peak and 
nadir of the flow velocity profiles were observed for 4 h after 
the onset of administration of agents. Serial blood samples 
were collected before and 1 and 3 h after the onset of 
administration of agents for measurement of platelet count 
and aggregation assessed ex vivo in platelet-rich plasma, 
activated partial thromboplastin time and prothrombin time. 
Samples were also obtained before and 45 rain after adminis- 
tration of the mimetic for analysis of platelet cyclic guanosine 
5'-monophosphate levels in platelet-rich plasma. 
In some rabbits, the site of carotid arterial injury was 
examined by scanning electron microscopy 4 h after the onset 
of administration of agents. Vessels were perfused in situ 
through the aorta with 0.2 tool/liter of phosphate-buffered 
saline followed by a solution of 1% paraformaldehyde and 
1.5% glutaraldehyde fixative in phosphate buffer (pH 7.4) at a 
pressure of 100 mm Hg. Vessels from animals exhibiting cyclic 
flow variations were perfused consistently at the time of peak 
flow velocity (i.e., just after a cyclic flow variation was regis- 
tered). The injured arterial segment was excised and immersed 
in fixative for an additional 12 h, transferred into phosphate 
buffer and stored at 4°C before processing. 
Hematologic measurements. Arterial blood was drawn into 
plastic syringes containing 3.8% sodium citrate solution (9 vol 
of blood/1 vol of sodium citrate). Platelet-rich plasma was 
obtained by centrifugation of the blood sample at 160 g for 
10 min at room temperature. Platelet count was measured and 
adjusted to 3 x 10S/ml by addition of platelet-poor plasma 
obtained by recentrifugation f the remaining plasma t 1,500 g
for 10 min. Aggregation of the count-adjusted platelet-rich 
plasma was measured turbidometrically with an aggregometer 
(Payton Associates). Collagen (4 to 8 p~g/ml) (Chronolog) and 
thrombin (0.5 to 0.75 U/ml) (Chronolog) were used as ago- 
nists. The minimal (threshold) concentration of each agonist 
required to induce ->50% change of light transmission was 
determined inbaseline samples and then used in serial samples 
to assess changes in aggregation after treatment. Activated 
partial thromboplastin and prothrombin times were measured 
in citrated plasma samples with use of an automated coagula- 
tion timer (Coag-a-mate, Organon Teknika), as described by 
the manufacturer. 
Measurement of platelet cyclic guanosine 5'-monophosphate. 
Cyclic guanosine 5'-monophosphate levels in platelets were 
measured in platelet-rich plasma to which 1 mmol/liter of 
3-isobutyl-L-methyl-xanthine (Sigma Corp.) was added to in- 
hibit phosphodiesterase ctivity. Samples were frozen in liquid 
JACC Vol. 25, No. 1 MENG ET AL. 271 
January 1995:269-75 SUPEROXIDE DISMUTASE INHIBITS THROMBUS IN DAMAGED ARTERIES 
nitrogen and stored at -70°C before assay. Each was thawed 
and 250/zl incubated with an equal volume of 20% trichloro- 
acetic acid on ice for 5 min. The mixture was centrifuged at 800 
g for 5 min and the supernatant removed. Trichloroacetic acid 
in the supernatant was extracted by four washes with water- 
saturated ether and the sample evaporated to dryness in a 
Speed-vac. The sample was reconstituted in buffer and assayed 
with use of an enzyme immunoassay kit (Amersham). Results 
were expressed as fmol of cyclic guanosine 5'-monophosphate/ 
106 platelets. 
Scanning electron microscopy. Vessel segments were post- 
fixed with 1.0% osmium tetroxide at room temperature, fol- 
lowed by several washes in phosphate buffer. The segments 
were pinned onto sheets of silicon rubber, dehydrated in an 
ascending series of ethanol and dried by the critical point 
method in a Polaron G-3000 critical point dryer. The dried 
specimens were mounted on aluminum stubs with sticky tabs, 
rimmed with silver colloidal paint and coated with gold in a 
Polaron G-5000 sputter coater. They were observed using a 
Hitachi S-450 scanning electron microscope, operated at 20 kV. 
Statistics. All results are expressed as mean value _+ SEM. 
Differences within and between groups over time were evalu- 
ated with use of a two-way analysis of variance for repeated 
measurements incorporating a Duncan's post hoc test to define 
the significance of observed ifferences. A p value <0.05 was 
considered significant. 
Resu l ts  
Frequency of cyclic flow variations. Spontaneous cyclic 
flow variations were induced in all 39 rabbits with vessel injury 
and stenosis. They were unchanged in frequency and magni- 
tude for 4 h in rabbits given buffer vehicle (Fig. 1), and their 
incidence was not associated with changes in blood pressure 
(Fig. 2). Administration of 12 mg/kg of the mimetic of super- 
oxide dismutase inhibited cyclic flow variations ignificantly 
from 15 + 1/30 min at baseline to 3 _+ 1/30 rain at 4 h. Similar 
results were obtained with administration fthe same dose (on 
a weight basis) of copper/zinc superoxide dismutase (Fig. 1). A 
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Figure 1. Inhibition of cyclic flow variations after administration of 
different doses of a mimetic of superoxide ismutase (SODm, boluses 
of 4 mg/kg at 0 and 15 min for 8 mg/kg and at 0, 15 and 30 min for 
12 mg/kg), bovine copper/zinc superoxide ismutase (SOD, boluses of 
4 mg at 0, 15 and 30 min), aspirin (bolus at 0 min) or buffer used as the 
vehicle for superoxide dismutase. Data points are values calculated 
from cyclic flow variations recorded over 30-min intervals. *p < 0.005 
compared with baseline and vehicle-treated animals. 
lower dose of mimetic (8 mg/kg) also inhibited cyclic flow 
variations markedly, but the frequency was partially restored 
1 h after drug administration i  three of five rabbits. Aspirin 
inhibited cyclic flow variations comparable to that observed 
with the high dose of superoxide dismutase (Fig. 1) as did 
Figure 2. Recordings of phasic arotid blood flow velocity and both 
pulsatile and mean (2) arterial blood pressure measured simulta- 
neously in an animal after induction of vessel injury and stenosis 
(Baseline), which resulted in spontaneous cyclic flow variations (ar- 
rows) during administration f 4 mg/kg of the mimetic of superoxide 
dismutase (SOD) (total dose of 12 mg/kg) and 30 min after the start of 
infusion of NG-monomethyl-L-arginine (L-NMMA). Cyclic flow varia- 
tions were not associated with changes inblood pressure. Administra- 
tion of the mimetic induced a transient decrease in blood pressure 
(star) and abolished cyclic flow variations, whereas concomitant 
administration f the inhibitor of nitric oxide production resulted in 
the return of cyclic flow variations and increased mean blood pressure. 
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Figure 3. Changes in aortic mean arterial blood pressure xpressed as 
percentages ofbaseline values after intravenous administration of the 
mimetic of superoxide dismutase (SODm), either with or without 
injury and stenosis induced in a carotid artery, or administration of 
copper/zinc superoxide dismutase, aspirin or vehicle in the presence of 
vessel injury and stenosis. Values at baseline were 71 + 3 mm Hg for 
the mimetic with vessel injury, 65 _+ 4 mm Hg for the mimetic without 
vessel injury, 69 -+ 8 mm Hg for superoxide dismutase, 57 -+ 5 mm Hg 
for aspirin and 67 -+ 4 mm Hg for vehicle. In the absence of injury, 
blood pressure changed minimally after administration of mimetic. 
• p < 0.001 compared with baseline values. 
continuous infusion of nitroglycerin (from 15 ± 1/30 rain at 
baseline to 1 +_ 1/30 min after 4 h, n = 4). 
Hemodynamic variables and carotid flow velocity. In the 
presence of vessel injury and stenosis, bolus injections of the 
mimetic caused a transient decrease in mean arterial blood 
pressure of between 10 and 15 mm Hg that recovered within 
2 min (Fig. 2). In animals given either superoxide dismutase or 
the mimetic, a more modest but sustained ecrease in blood 
pressure was observed compared with vehicle- and aspirin- 
treated animals (Fig. 3). A constant infusion of nitroglycerin 
also decreased blood pressure from 53 ± 3 to 40 __ 5 mm Hg 
after 4 h. However, in the absence of vessel injury, blood 
pressure was decreased minimally after administration of the 
mimetic (Fig. 3). Heart rate was not changed significantly in 
any group (data not shown). 
Administration of superoxide dismutase or the mimetic 
induced a sustained increase of peak flow velocity in the 
injured carotid artery (Fig. 4). Changes were minimal in 
animals given vehicle or aspirin and in those given the mimetic 
in the absence of vessel injury (Fig. 4). Nadir flow velocity 
increased also in injured vessels beginning 30 min after the 
administration of superoxide dismutase (139 _+ 13% of base- 
line velocity after 12 mg/kg) or the mimetic (145 _+ 13% of 
baseline after 8 mg/kg and 149 ± 8% after 12 mg/kg). Similar 
effects were observed in animals given nitroglycerin (data not 
shown)• 
Hematologic findings. Platelet count was unchanged ur- 
ing experiments except in vehicle-treated rabbits in which the 
count decreased from 3.0 _+ 0.2 × 10 s platelets/ml at baseline 
to 2.2 ± 0.5 × 108 platelets/ml after 4 h (p < 0.05, n = 5). 
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Figure 4. Changes in peak flow velocity in the carotid artery assessed 
with a proximal Doppler probe after administration of the mimetic of 
superoxide dismutase (SODm), either with or without distal injury and 
stenosis of the vessel, or after administration ofcopper/zinc superoxide 
dismutase, aspirin or vehicle in the presence of injury and stenosis of 
the carotid artery. In the absence of vessel injury, peak flow velocity 
was changed minimally after administration of the mimetic. *p < 0.05 
compared with baseline values. 
Platelet aggregation i platelet-rich plasma assessed ex vivo in 
response to added thrombin or collagen was not changed after 
administration of superoxide dismutase or the mimetic. How- 
ever, in animals given aspirin, platelet aggregation was de- 
creased from 60 + 3% transmittance atbaseline to 21 _+ 9% 
transmittance 1 h after aspirin and 17 -+ 10% after 4 h (p < 
0.05, n = 5). Activated partial thromboplastin and prothrom- 
bin times were not changed significantly in any of the groups of 
animals (data not shown). 
Cyclic guanosine 5'-monophosphate l vels in platelets. 
Levels increased markedly from 2.4 _+ 0.5 fmol/106 platelets at 
baseline to 4.9 __ 0.6 fmol/106 platelets 45 min after adminis- 
tration of 12 mg/kg of the mimetic of superoxide dismutase 
(p < 0.03, n = 6). 
Effects of NC-monomethyl-L-arginine. Inhibition of nitric 
oxide production with NG-monomethyl-L-arginine fused af- 
ter administration of the mimetic of superoxide dismutase 
restored cyclic flow variations within 7 to 9 min in three of four 
rabbits (Fig. 2) and resulted in a decrease in carotid flow 
velocity in all four (from 130 ± 11% of baseline to 105 _+ 6% 
of baseline after inhibitor, p < 0.05). Mean arterial blood 
pressure was increased from 66 _+ 3 to 87 _+ 7 mm Hg (p = 
0.05) during inhibitor infusion. Within 10 min after the end of 
the infusion of inhibitor, cyclic flow variations were again 
attenuated, carotid flow velocity increased, and blood pressure 
decreased as with the mimetic alone. Lower doses of N G- 
monomethyl-L-arginine (5 or 40 mg/kg) did not renew cyclic 
flow variations and did not change carotid flow velocity (data 
not shown). 
Scanning electron microscopy. In nine rabbits, the injured 
carotid arteries were examined by scanning electron micros- 
copy. Accumulation of platelet-rich thrombus at the site of 
injury was diminished in animals given the mimetic of super- 
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Figure 5. Scanning electron micrographs of injured ca- 
rotid arteries and associated thrombi from two animals 4 h 
after the induction ofinjury. Top, Artery from an animal 
given buffer vehicle. Inset is a low magnification f the 
artery incised longitudinally showing the clamp-injured 
segment as a transverse band devoid of endothelium and 
with considerable thrombus attached tothe subendothe- 
lium. The thrombus (high magnification) comprises plate- 
lets, red cells and fibrin. Bottom, Artery from an animal 
given the mimetic of superoxide ismutase. Thrombus i
diminished compared with the vehicle-treated animal and 
comprises primarily platelets. 
oxide dismutase (n -- 5) as well as in those given aspirin (n = 
2) compared with those given vehicle (n = 2) (Fig. 5). Indeed, 
the injured surface in animals given the mimetic appeared to 
be covered only with a thin layer of platelets (Fig. 5). 
Discussion 
The results show that administration of superoxide dis- 
mutase or a synthetic low molecular weight mimetic inhibit 
cyclic flow variations in damaged and stenotic arotid arteries 
(Fig. 1 and 2) and decrease accumulation of platelet-rich 
thrombus at the site of vascular injury (Fig. 5). This is 
accompanied byreduced mean arterial blood pressure (Fig. 3) 
and increased blood flow velocity in the injured vessel (Fig. 4), 
similar to the effects observed with nitroglycerin, which is 
metabolized tonitric oxide in vivo (24). The effects of super- 
oxide dismutase are reversed by infusion of N~-monomethyl - 
L-arginine (Fig. 2), an inhibitor of nitric oxide production (25). 
Thus, inhibition of cyclic flow variations and vasodilation 
induced by superoxide dismutase appear to reflect increased 
endogenous nitric oxide, possibly derived from endothelium 
located proximal to the site of vessel injury and stenosis where 
high shear could induce its synthesis (26). 
Cyclic variations in blood flow analogous to those induced 
in this study have been observed in both peripheral and 
coronary arteries of patients (6-8). By carefully controlling the 
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extent of vessel injury induced, we modified the experimental 
preparation reported initially by Folts et al. (4) to one exhib- 
iting totally spontaneous cyclic flow variations with a stable 
frequency for at least 4 h. 
Antiplatelet agents, including aspirin (4), antagonists of 
thromboxane (27), serotonin (28) and platelet-activating factor 
(29,30), all abolish cyclic flow variations, as does L-arginine 
(20), the precursor of nitric oxide, nitroglycerin (31) and 
sodium nitroprusside (32), consistent with a mechanism for 
their induction involving platelet activation. Our data confirm 
previous results (9) showing attenuation of cyclic flow varia- 
tions by administration of superoxide dismutase consistent 
with oxygen free radicals elaborated by damaged endothelial 
cells (10), leucocytes (11) and smooth muscle cells contributing 
to local activation of platelets and inactivation of endogenous 
nitric oxide. 
Increased endogenous levels of nitric oxide resulting from 
dismutation of superoxide anion by superoxide dismutase or 
the mimetic could account for the observed vasodilation and 
the twofold increase in the levels of platelet cyclic guanosine 
5'-monophosphate. Both of these responses could contribute 
to the observed ecrease in cyclic flow variations. Changes in 
flow velocity and blood pressure were minimal in animals given 
the mimetic in the absence of vascular injury and stenosis 
indicating the dependence of nitric oxide release on vessel 
damage or stenosis, or both. Previous tudies have documented 
that flow-induced shear stress and thrombin both increase 
nitric oxide released from endothelium (21,26,33,34). Thus, by 
removing superoxide anion, superoxide dismutase may have 
unmasked the nitric oxide released in response to shear forces 
and thrombin generation associated with high grade stenosis. 
Inhibition of endothelium-derived nitric oxide release during 
infusion of NG-monomethyl-c-arginine may explain the return 
of cyclic flow variations (Fig. 2). 
Despite bolus administration, superoxide dismutase and 
the mimetic produced prolonged inhibition of cyclic flow 
variations, increased flow velocity and lowered blood pres- 
sure. This may have resulted from prolonged association 
of superoxide dismutase with heparin binding sites on endo- 
thelium documented previously (35). Thus, as generation of 
nitric oxide as well as superoxide anion persisted at the site 
of stenosis, prolonged availability of superoxide dismutase 
could have protected the endogenous nitric oxide from inacti- 
vation. 
Clinical implications. Unstable angina is characterized by 
intermittent accumulation of platelets at sites of coronary 
stenosis (3). The prolonged inhibitory effects of superoxide 
dismutase or its mimetic on local platelet adhesion and acti- 
vation in an injured artery may be useful to attenuate unstable 
angina and warrants further investigation. 
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